TY - JOUR
T1 - Use of the Abrysvo Vaccine in Pregnancy to Prevent Respiratory Syncytial Virus in Infants
T2 - A Review
AU - Patel, Dhanvi
AU - Chawla, Jyotsna
AU - Blavo, Cyril
PY - 2024/8/31
Y1 - 2024/8/31
N2 - The FDA's approval of Pfizer’s new respiratory syncytial virus (RSV) prefusion (preF) vaccine, Abrysvo, marks a critical milestone in infant health and well-being by preventing lower respiratory tract infections in the most vulnerable. The vaccine has been approved for administration to pregnant women at 32 to 36 weeks of gestation and elderly people over 60. This review explores the Abrysvo vaccine, detailing its mechanism, efficacy, safety, and adverse events. It aims to inform healthcare providers about this vital method for safeguarding infant respiratory health through maternal immunization.
AB - The FDA's approval of Pfizer’s new respiratory syncytial virus (RSV) prefusion (preF) vaccine, Abrysvo, marks a critical milestone in infant health and well-being by preventing lower respiratory tract infections in the most vulnerable. The vaccine has been approved for administration to pregnant women at 32 to 36 weeks of gestation and elderly people over 60. This review explores the Abrysvo vaccine, detailing its mechanism, efficacy, safety, and adverse events. It aims to inform healthcare providers about this vital method for safeguarding infant respiratory health through maternal immunization.
KW - Abrysvo
KW - Adverse effects
KW - Fda approved
KW - Infant health
KW - Maternal vaccination
KW - Pregnancy
KW - Respiratory syncytial virus
KW - Rsv vaccine
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=novaseuniv&SrcAuth=WosAPI&KeyUT=WOS:001304458200008&DestLinkType=FullRecord&DestApp=WOS_CPL
U2 - 10.7759/cureus.68349
DO - 10.7759/cureus.68349
M3 - Review article
C2 - 39355078
VL - 16
JO - Cureus Journal of Medical Science
JF - Cureus Journal of Medical Science
IS - 8
M1 - e68349
ER -